<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240414063459
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240414063459" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 14 Apr 2024 10:35:00 +0000</lastbuilddate>
<pubDate>Sat, 13 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The importance of prevention in high-risk patients: peripheral artery disease, renal failure, and diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38614813/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 14;45(15):1287-1290. doi: 10.1093/eurheartj/ehae218.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38614813/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38614813</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae218>10.1093/eurheartj/ehae218</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38614813</guid>
<pubDate>Sat, 13 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-04-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The importance of prevention in high-risk patients: peripheral artery disease, renal failure, and diabetes</dc:title>
<dc:identifier>pmid:38614813</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae218</dc:identifier>
</item>
<item>
<title>RNA genome packaging and capsid assembly of bluetongue virus visualized in host cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38614100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>Unlike those of double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), and ssRNA viruses, the mechanism of genome packaging of dsRNA viruses is poorly understood. Here, we combined the techniques of high-resolution cryoelectron microscopy (cryo-EM), cellular cryoelectron tomography (cryo-ET), and structure-guided mutagenesis to investigate genome packaging and capsid assembly of bluetongue virus (BTV), a member of the Reoviridae family of dsRNA viruses. A total of eleven assembly states of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 5:S0092-8674(24)00299-X. doi: 10.1016/j.cell.2024.03.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Unlike those of double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), and ssRNA viruses, the mechanism of genome packaging of dsRNA viruses is poorly understood. Here, we combined the techniques of high-resolution cryoelectron microscopy (cryo-EM), cellular cryoelectron tomography (cryo-ET), and structure-guided mutagenesis to investigate genome packaging and capsid assembly of bluetongue virus (BTV), a member of the Reoviridae family of dsRNA viruses. A total of eleven assembly states of BTV capsid were captured, with resolutions up to 2.8 Å, with most visualized in the host cytoplasm. ATPase VP6 was found underneath the vertices of capsid shell protein VP3 as an RNA-harboring pentamer, facilitating RNA packaging. RNA packaging expands the VP3 shell, which then engages middle- and outer-layer proteins to generate infectious virions. These revealed "duality" characteristics of the BTV assembly mechanism reconcile previous contradictory co-assembly and core-filling models and provide insights into the mysterious RNA packaging and capsid assembly of Reoviridae members and beyond.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38614100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38614100</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.007>10.1016/j.cell.2024.03.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38614100</guid>
<pubDate>Sat, 13 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Xian Xia</dc:creator>
<dc:creator>Po-Yu Sung</dc:creator>
<dc:creator>Michael W Martynowycz</dc:creator>
<dc:creator>Tamir Gonen</dc:creator>
<dc:creator>Polly Roy</dc:creator>
<dc:creator>Z Hong Zhou</dc:creator>
<dc:date>2024-04-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RNA genome packaging and capsid assembly of bluetongue virus visualized in host cells</dc:title>
<dc:identifier>pmid:38614100</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.007</dc:identifier>
</item>
<item>
<title>NINJ1 mediates plasma membrane rupture by cutting and releasing membrane disks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38614101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>The membrane protein NINJ1 mediates plasma membrane rupture in pyroptosis and other lytic cell death pathways. Here, we report the cryo-EM structure of a NINJ1 oligomer segmented from NINJ1 rings. Each NINJ1 subunit comprises amphipathic (⍺1, ⍺2) and transmembrane (TM) helices (⍺3, ⍺4) and forms a chain of subunits, mainly by the TM helices and ⍺1. ⍺3 and ⍺4 are kinked, and the Gly residues are important for function. The NINJ1 oligomer possesses a concave hydrophobic side that should face the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 2:S0092-8674(24)00300-3. doi: 10.1016/j.cell.2024.03.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The membrane protein NINJ1 mediates plasma membrane rupture in pyroptosis and other lytic cell death pathways. Here, we report the cryo-EM structure of a NINJ1 oligomer segmented from NINJ1 rings. Each NINJ1 subunit comprises amphipathic (⍺1, ⍺2) and transmembrane (TM) helices (⍺3, ⍺4) and forms a chain of subunits, mainly by the TM helices and ⍺1. ⍺3 and ⍺4 are kinked, and the Gly residues are important for function. The NINJ1 oligomer possesses a concave hydrophobic side that should face the membrane and a convex hydrophilic side formed by ⍺1 and ⍺2, presumably upon activation. This structural observation suggests that NINJ1 can form membrane disks, consistent with membrane fragmentation by recombinant NINJ1. Live-cell and super-resolution imaging uncover ring-like structures on the plasma membrane that are released into the culture supernatant. Released NINJ1 encircles a membrane inside, as shown by lipid staining. Therefore, NINJ1-mediated membrane disk formation is different from gasdermin-mediated pore formation, resulting in membrane loss and plasma membrane rupture.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38614101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38614101</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.008>10.1016/j.cell.2024.03.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38614101</guid>
<pubDate>Sat, 13 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Liron David</dc:creator>
<dc:creator>Jazlyn P Borges</dc:creator>
<dc:creator>L Robert Hollingsworth</dc:creator>
<dc:creator>Allen Volchuk</dc:creator>
<dc:creator>Isabelle Jansen</dc:creator>
<dc:creator>Evelyn Garlick</dc:creator>
<dc:creator>Benjamin E Steinberg</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:date>2024-04-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>NINJ1 mediates plasma membrane rupture by cutting and releasing membrane disks</dc:title>
<dc:identifier>pmid:38614101</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.008</dc:identifier>
</item>
<item>
<title>ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38614099/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>Cancer immunotherapy has transformed treatment possibilities, but its effectiveness differs significantly among patients, indicating the presence of alternative pathways for immune evasion. Here, we show that ITPRIPL1 functions as an inhibitory ligand of CD3ε, and its expression inhibits T cells in the tumor microenvironment. The binding of ITPRIPL1 extracellular domain to CD3ε on T cells significantly decreased calcium influx and ZAP70 phosphorylation, impeding initial T cell activation....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 5:S0092-8674(24)00310-6. doi: 10.1016/j.cell.2024.03.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cancer immunotherapy has transformed treatment possibilities, but its effectiveness differs significantly among patients, indicating the presence of alternative pathways for immune evasion. Here, we show that ITPRIPL1 functions as an inhibitory ligand of CD3ε, and its expression inhibits T cells in the tumor microenvironment. The binding of ITPRIPL1 extracellular domain to CD3ε on T cells significantly decreased calcium influx and ZAP70 phosphorylation, impeding initial T cell activation. Treatment with a neutralizing antibody against ITPRIPL1 restrained tumor growth and promoted T cell infiltration in mouse models across various solid tumor types. The antibody targeting canine ITPRIPL1 exhibited notable therapeutic efficacy against naturally occurring tumors in pet clinics. These findings highlight the role of ITPRIPL1 (or CD3L1, CD3ε ligand 1) in impeding T cell activation during the critical "signal one" phase. This discovery positions ITPRIPL1 as a promising therapeutic target against multiple tumor types.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38614099/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38614099</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.019>10.1016/j.cell.2024.03.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38614099</guid>
<pubDate>Sat, 13 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Shouyan Deng</dc:creator>
<dc:creator>Yibo Zhang</dc:creator>
<dc:creator>Huanbin Wang</dc:creator>
<dc:creator>Wenhua Liang</dc:creator>
<dc:creator>Lu Xie</dc:creator>
<dc:creator>Ning Li</dc:creator>
<dc:creator>Yuan Fang</dc:creator>
<dc:creator>Yiting Wang</dc:creator>
<dc:creator>Jiayang Liu</dc:creator>
<dc:creator>Hao Chi</dc:creator>
<dc:creator>Yufan Sun</dc:creator>
<dc:creator>Rui Ye</dc:creator>
<dc:creator>Lishen Shan</dc:creator>
<dc:creator>Jiawei Shi</dc:creator>
<dc:creator>Zan Shen</dc:creator>
<dc:creator>Yonggang Wang</dc:creator>
<dc:creator>Shuhang Wang</dc:creator>
<dc:creator>Jean-Philippe Brosseau</dc:creator>
<dc:creator>Feng Wang</dc:creator>
<dc:creator>Grace Liu</dc:creator>
<dc:creator>Yingfei Quan</dc:creator>
<dc:creator>Jie Xu</dc:creator>
<dc:date>2024-04-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion</dc:title>
<dc:identifier>pmid:38614099</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.019</dc:identifier>
</item>
<item>
<title>Direct observation of a condensate effect on super-enhancer controlled gene bursting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38614098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 12:S0092-8674(24)00362-3. doi: 10.1016/j.cell.2024.04.001. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38614098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38614098</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.001>10.1016/j.cell.2024.04.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38614098</guid>
<pubDate>Sat, 13 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Manyu Du</dc:creator>
<dc:creator>Simon Hendrik Stitzinger</dc:creator>
<dc:creator>Jan-Hendrik Spille</dc:creator>
<dc:creator>Won-Ki Cho</dc:creator>
<dc:creator>Choongman Lee</dc:creator>
<dc:creator>Mohammed Hijaz</dc:creator>
<dc:creator>Andrea Quintana</dc:creator>
<dc:creator>Ibrahim I Cissé</dc:creator>
<dc:date>2024-04-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Direct observation of a condensate effect on super-enhancer controlled gene bursting</dc:title>
<dc:identifier>pmid:38614098</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.001</dc:identifier>
</item>
<item>
<title>Chromatin context-dependent regulation and epigenetic manipulation of prime editing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38608704/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>We set out to exhaustively characterize the impact of the cis-chromatin environment on prime editing, a precise genome engineering tool. Using a highly sensitive method for mapping the genomic locations of randomly integrated reporters, we discover massive position effects, exemplified by editing efficiencies ranging from ∼0% to 94% for an identical target site and edit. Position effects on prime editing efficiency are well predicted by chromatin marks, e.g., positively by H3K79me2 and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 5:S0092-8674(24)00311-8. doi: 10.1016/j.cell.2024.03.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We set out to exhaustively characterize the impact of the cis-chromatin environment on prime editing, a precise genome engineering tool. Using a highly sensitive method for mapping the genomic locations of randomly integrated reporters, we discover massive position effects, exemplified by editing efficiencies ranging from ∼0% to 94% for an identical target site and edit. Position effects on prime editing efficiency are well predicted by chromatin marks, e.g., positively by H3K79me2 and negatively by H3K9me3. Next, we developed a multiplex perturbational framework to assess the interaction of trans-acting factors with the cis-chromatin environment on editing outcomes. Applying this framework to DNA repair factors, we identify HLTF as a context-dependent repressor of prime editing. Finally, several lines of evidence suggest that active transcriptional elongation enhances prime editing. Consistent with this, we show we can robustly decrease or increase the efficiency of prime editing by preceding it with CRISPR-mediated silencing or activation, respectively.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38608704/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38608704</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.020>10.1016/j.cell.2024.03.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38608704</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaoyi Li</dc:creator>
<dc:creator>Wei Chen</dc:creator>
<dc:creator>Beth K Martin</dc:creator>
<dc:creator>Diego Calderon</dc:creator>
<dc:creator>Choli Lee</dc:creator>
<dc:creator>Junhong Choi</dc:creator>
<dc:creator>Florence M Chardon</dc:creator>
<dc:creator>Troy A McDiarmid</dc:creator>
<dc:creator>Riza M Daza</dc:creator>
<dc:creator>Haedong Kim</dc:creator>
<dc:creator>Jean-Benoît Lalanne</dc:creator>
<dc:creator>Jenny F Nathans</dc:creator>
<dc:creator>David S Lee</dc:creator>
<dc:creator>Jay Shendure</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Chromatin context-dependent regulation and epigenetic manipulation of prime editing</dc:title>
<dc:identifier>pmid:38608704</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.020</dc:identifier>
</item>
<item>
<title>A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38608703/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>Knudson's "two-hit" paradigm posits that carcinogenesis requires inactivation of both copies of an autosomal tumor suppressor gene. Here, we report that the glycolytic metabolite methylglyoxal (MGO) transiently bypasses Knudson's paradigm by inactivating the breast cancer suppressor protein BRCA2 to elicit a cancer-associated, mutational single-base substitution (SBS) signature in nonmalignant mammary cells or patient-derived organoids. Germline monoallelic BRCA2 mutations predispose to these...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 8:S0092-8674(24)00255-1. doi: 10.1016/j.cell.2024.03.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Knudson's "two-hit" paradigm posits that carcinogenesis requires inactivation of both copies of an autosomal tumor suppressor gene. Here, we report that the glycolytic metabolite methylglyoxal (MGO) transiently bypasses Knudson's paradigm by inactivating the breast cancer suppressor protein BRCA2 to elicit a cancer-associated, mutational single-base substitution (SBS) signature in nonmalignant mammary cells or patient-derived organoids. Germline monoallelic BRCA2 mutations predispose to these changes. An analogous SBS signature, again without biallelic BRCA2 inactivation, accompanies MGO accumulation and DNA damage in Kras-driven, Brca2-mutant murine pancreatic cancers and human breast cancers. MGO triggers BRCA2 proteolysis, temporarily disabling BRCA2's tumor suppressive functions in DNA repair and replication, causing functional haploinsufficiency. Intermittent MGO exposure incites episodic SBS mutations without permanent BRCA2 inactivation. Thus, a metabolic mechanism wherein MGO-induced BRCA2 haploinsufficiency transiently bypasses Knudson's two-hit requirement could link glycolysis activation by oncogenes, metabolic disorders, or dietary challenges to mutational signatures implicated in cancer evolution.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38608703/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38608703</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.006>10.1016/j.cell.2024.03.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38608703</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Li Ren Kong</dc:creator>
<dc:creator>Komal Gupta</dc:creator>
<dc:creator>Andy Jialun Wu</dc:creator>
<dc:creator>David Perera</dc:creator>
<dc:creator>Roland Ivanyi-Nagy</dc:creator>
<dc:creator>Syed Moiz Ahmed</dc:creator>
<dc:creator>Tuan Zea Tan</dc:creator>
<dc:creator>Shawn Lu-Wen Tan</dc:creator>
<dc:creator>Alessandra Fuddin</dc:creator>
<dc:creator>Elayanambi Sundaramoorthy</dc:creator>
<dc:creator>Grace Shiqing Goh</dc:creator>
<dc:creator>Regina Tong Xin Wong</dc:creator>
<dc:creator>Ana S H Costa</dc:creator>
<dc:creator>Callum Oddy</dc:creator>
<dc:creator>Hannan Wong</dc:creator>
<dc:creator>C Pawan K Patro</dc:creator>
<dc:creator>Yun Suen Kho</dc:creator>
<dc:creator>Xiao Zi Huang</dc:creator>
<dc:creator>Joan Choo</dc:creator>
<dc:creator>Mona Shehata</dc:creator>
<dc:creator>Soo Chin Lee</dc:creator>
<dc:creator>Boon Cher Goh</dc:creator>
<dc:creator>Christian Frezza</dc:creator>
<dc:creator>Jason J Pitt</dc:creator>
<dc:creator>Ashok R Venkitaraman</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2</dc:title>
<dc:identifier>pmid:38608703</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.006</dc:identifier>
</item>
<item>
<title>Problem choice and decision trees in science and engineering</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38608651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>Scientists and engineers often spend days choosing a problem and years solving it. This imbalance limits impact. Here, we offer a framework for problem choice: prompts for ideation, guidelines for evaluating impact and likelihood of success, the importance of fixing one parameter at a time, and opportunities afforded by failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 11;187(8):1828-1833. doi: 10.1016/j.cell.2024.03.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Scientists and engineers often spend days choosing a problem and years solving it. This imbalance limits impact. Here, we offer a framework for problem choice: prompts for ideation, guidelines for evaluating impact and likelihood of success, the importance of fixing one parameter at a time, and opportunities afforded by failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38608651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38608651</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.012>10.1016/j.cell.2024.03.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38608651</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael A Fischbach</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Problem choice and decision trees in science and engineering</dc:title>
<dc:identifier>pmid:38608651</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.012</dc:identifier>
</item>
<item>
<title>Ending "domestic helicopter research"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38608650/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>"Helicopter research" refers to a practice where researchers from wealthier countries conduct studies in lower-income countries with little involvement of local researchers or community members. This practice also occurs domestically. In this Commentary, we outline strategies to curb domestic helicopter research and to foster equity-centered collaborations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 11;187(8):1823-1827. doi: 10.1016/j.cell.2024.02.027.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">"Helicopter research" refers to a practice where researchers from wealthier countries conduct studies in lower-income countries with little involvement of local researchers or community members. This practice also occurs domestically. In this Commentary, we outline strategies to curb domestic helicopter research and to foster equity-centered collaborations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38608650/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38608650</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.027>10.1016/j.cell.2024.02.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38608650</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>W Marcus Lambert</dc:creator>
<dc:creator>Marlene Camacho-Rivera</dc:creator>
<dc:creator>Carla Boutin-Foster</dc:creator>
<dc:creator>Moro Salifu</dc:creator>
<dc:creator>Wayne J Riley</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ending "domestic helicopter research"</dc:title>
<dc:identifier>pmid:38608650</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.027</dc:identifier>
</item>
<item>
<title>Self-amplifying RNA COVID-19 vaccine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38608649/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 11;187(8):1822-1822.e1. doi: 10.1016/j.cell.2024.03.018.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38608649/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38608649</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.018>10.1016/j.cell.2024.03.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38608649</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Christopher J Wayne</dc:creator>
<dc:creator>Anna K Blakney</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Self-amplifying RNA COVID-19 vaccine</dc:title>
<dc:identifier>pmid:38608649</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.018</dc:identifier>
</item>
<item>
<title>Elliott Dan Kieff, MD, PhD (1943-2024)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38608648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 11;187(8):1819-1821. doi: 10.1016/j.cell.2024.02.038.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38608648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38608648</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.038>10.1016/j.cell.2024.02.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38608648</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nancy Raab-Traub</dc:creator>
<dc:creator>Benjamin E Gewurz</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Elliott Dan Kieff, MD, PhD (1943-2024)</dc:title>
<dc:identifier>pmid:38608648</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.038</dc:identifier>
</item>
<item>
<title>Peripheral artery disease and outcomes: how can we improve risk prediction?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae154. doi: 10.1093/eurheartj/ehae154. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38607986</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae154>10.1093/eurheartj/ehae154</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607986</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mounica Yanamandala</dc:creator>
<dc:creator>Guillaume Goudot</dc:creator>
<dc:creator>Marie Denise Gerhard-Herman</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Peripheral artery disease and outcomes: how can we improve risk prediction?</dc:title>
<dc:identifier>pmid:38607986</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae154</dc:identifier>
</item>
<item>
<title>Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study revealed that crosstalk between tumour cells and cardiomyocytes during chemotherapy could disturb cardiac energy metabolism and impair heart function. IL-1α neutralizing antibody treatment is a promising strategy for alleviating chemotherapy-induced cardiotoxicity in AML patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae188. doi: 10.1093/eurheartj/ehae188. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients with acute myeloid leukaemia (AML) suffer from severe myocardial injury during daunorubicin (DNR)-based chemotherapy and are at high risk of cardiac mortality. The crosstalk between tumour cells and cardiomyocytes might play an important role in chemotherapy-related cardiotoxicity, but this has yet to be demonstrated. This study aimed to identify its underlying mechanism and explore potential therapeutic targets.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Cardiac tissues were harvested from an AML patient after DNR-based chemotherapy and were subjected to single-nucleus RNA sequencing. Cardiac metabolism and function were evaluated in AML mice after DNR treatment by using positron emission tomography, magnetic resonance imaging, and stable-isotope tracing metabolomics. Plasma cytokines were screened in AML mice after DNR treatment. Genetically modified mice and cell lines were used to validate the central role of the identified cytokine and explore its downstream effectors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the AML patient, disruption of cardiac metabolic homeostasis was associated with heart dysfunction after DNR-based chemotherapy. In AML mice, cardiac fatty acid utilization was attenuated, resulting in cardiac dysfunction after DNR treatment, but these phenotypes were not observed in similarly treated tumour-free mice. Furthermore, tumour cell-derived interleukin (IL)-1α was identified as a primary factor leading to DNR-induced cardiac dysfunction and administration of an anti-IL-1α neutralizing antibody could improve cardiac functions in AML mice after DNR treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study revealed that crosstalk between tumour cells and cardiomyocytes during chemotherapy could disturb cardiac energy metabolism and impair heart function. IL-1α neutralizing antibody treatment is a promising strategy for alleviating chemotherapy-induced cardiotoxicity in AML patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38607560</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae188>10.1093/eurheartj/ehae188</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607560</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Xingliang Zhou</dc:creator>
<dc:creator>Yiwei Liu</dc:creator>
<dc:creator>Yi Shen</dc:creator>
<dc:creator>Lijun Chen</dc:creator>
<dc:creator>Wenting Hu</dc:creator>
<dc:creator>Yi Yan</dc:creator>
<dc:creator>Bei Feng</dc:creator>
<dc:creator>Li Xiang</dc:creator>
<dc:creator>Yifan Zhu</dc:creator>
<dc:creator>Chenyu Jiang</dc:creator>
<dc:creator>Zihao Dai</dc:creator>
<dc:creator>Xu Huang</dc:creator>
<dc:creator>Liwei Wu</dc:creator>
<dc:creator>Tianyu Liu</dc:creator>
<dc:creator>Lijun Fu</dc:creator>
<dc:creator>Caiwen Duan</dc:creator>
<dc:creator>Shuhong Shen</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Hao Zhang</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α</dc:title>
<dc:identifier>pmid:38607560</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae188</dc:identifier>
</item>
<item>
<title>Prague ICU: free educational platform in the field of acute cardiovascular care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607441/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae200. doi: 10.1093/eurheartj/ehae200. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607441/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38607441</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae200>10.1093/eurheartj/ehae200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607441</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Michal Pazdernik</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prague ICU: free educational platform in the field of acute cardiovascular care</dc:title>
<dc:identifier>pmid:38607441</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae200</dc:identifier>
</item>
<item>
<title>The Nordic Cardio-Oncology Society: mission and future goals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607440/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae014. doi: 10.1093/eurheartj/ehae014. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607440/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38607440</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae014>10.1093/eurheartj/ehae014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607440</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Geeta Gulati</dc:creator>
<dc:creator>Agneta Månsson Broberg</dc:creator>
<dc:creator>Birgitte Vrou Offersen</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Nordic Cardio-Oncology Society: mission and future goals</dc:title>
<dc:identifier>pmid:38607440</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae014</dc:identifier>
</item>
<item>
<title>New devices of transcatheter interventions for structural heart disease in China</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae172. doi: 10.1093/eurheartj/ehae172. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38607335</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae172>10.1093/eurheartj/ehae172</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607335</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Yaling Han</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New devices of transcatheter interventions for structural heart disease in China</dc:title>
<dc:identifier>pmid:38607335</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae172</dc:identifier>
</item>
<item>
<title>Sing for a long and healthy life?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehad819. doi: 10.1093/eurheartj/ehad819. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38607286</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad819>10.1093/eurheartj/ehad819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607286</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ragavendra R Baliga</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sing for a long and healthy life?</dc:title>
<dc:identifier>pmid:38607286</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad819</dc:identifier>
</item>
<item>
<title>Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>Clinical risk scores based on traditional risk factors of atherosclerosis correlate imprecisely to an individual's complex pathophysiological predisposition to atherosclerosis and provide limited accuracy for predicting major adverse cardiovascular events (MACE). Over the past two decades, computed tomography scanners and techniques for coronary computed tomography angiography (CCTA) analysis have substantially improved, enabling more precise atherosclerotic plaque quantification and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae190. doi: 10.1093/eurheartj/ehae190. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Clinical risk scores based on traditional risk factors of atherosclerosis correlate imprecisely to an individual's complex pathophysiological predisposition to atherosclerosis and provide limited accuracy for predicting major adverse cardiovascular events (MACE). Over the past two decades, computed tomography scanners and techniques for coronary computed tomography angiography (CCTA) analysis have substantially improved, enabling more precise atherosclerotic plaque quantification and characterization. The accuracy of CCTA for quantifying stenosis and atherosclerosis has been validated in numerous multicentre studies and has shown consistent incremental prognostic value for MACE over the clinical risk spectrum in different populations. Serial CCTA studies have advanced our understanding of vascular biology and atherosclerotic disease progression. The direct disease visualization of CCTA has the potential to be used synergistically with indirect markers of risk to significantly improve prevention of MACE, pending large-scale randomized evaluation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38606889</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae190>10.1093/eurheartj/ehae190</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606889</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nick S Nurmohamed</dc:creator>
<dc:creator>Alexander R van Rosendael</dc:creator>
<dc:creator>Ibrahim Danad</dc:creator>
<dc:creator>Quyen Ngo-Metzger</dc:creator>
<dc:creator>Pam R Taub</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:creator>Gemma Figtree</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Judith Hsia</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Koen Nieman</dc:creator>
<dc:creator>James P Earls</dc:creator>
<dc:creator>Udo Hoffmann</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>James K Min</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography</dc:title>
<dc:identifier>pmid:38606889</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae190</dc:identifier>
</item>
<item>
<title>Rising stars in cardiology: George Abraham</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606883/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae192. doi: 10.1093/eurheartj/ehae192. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606883/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38606883</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae192>10.1093/eurheartj/ehae192</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606883</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising stars in cardiology: George Abraham</dc:title>
<dc:identifier>pmid:38606883</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae192</dc:identifier>
</item>
<item>
<title>Rising stars in cardiology: Florian A. Wenzl</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606876/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae186. doi: 10.1093/eurheartj/ehae186. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606876/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38606876</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae186>10.1093/eurheartj/ehae186</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606876</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising stars in cardiology: Florian A. Wenzl</dc:title>
<dc:identifier>pmid:38606876</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae186</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Renate Schnabel</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240414063459&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae182. doi: 10.1093/eurheartj/ehae182. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240414063459&v=2.18.0.post9+e462414">38606872</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae182>10.1093/eurheartj/ehae182</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606872</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Renate Schnabel</dc:title>
<dc:identifier>pmid:38606872</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae182</dc:identifier>
</item>





























</channel>
</rss>